Neomycin and Polymyxin B Sulfates Solution for Irrigation is a concentrated sterile antibiotic solution to be diluted for urinary bladder irrigation. Each mL contains neomycin sulfate equivalent to 40 mg neomycin base, 200,000 units polymyxin B sulfate, and Water for Injection, inactive ingredient: sulfuric acid. The 20-mL multiple dose vial contains, in addition to the above, 1 mg methylparaben (0.1%) added as a preservative. Neomycin sulfate, an antibiotic of the aminoglycoside group, is the sulfate salt of neomycin B and C produced by Streptomyces fradiae It has a potency equivalent to not less than 600 mcg of neomycin per mg.
Neomycin and Polymyxin B Sulfates Solution for Irrigation is indicated for short-term use (up to 10 days) as a continuous irrigant or rinse in the urinary bladder of abacteriuric patients to help prevent bacteriuria and gram-negative rod septicemia associated with the use of indwelling catheters.
Since organisms gain entrance to the bladder by way of, through, and around the catheter, significant bacteriuria is induced by bacterial multiplication in the bladder urine, in the mucoid film often present between catheter and urethra, and in other sites. Urinary tract infection may result from the repeated presence in the urine of large numbers of pathogenic bacteria. The use of closed systems with indwelling catheters has been shown to reduce the risk of infection. A three-way closed catheter system with constant neomycin-polymyxin B bladder rinse is indicated to prevent the development of infection while using indwelling catheters.
If uropathogens are isolated, they should be identified and tested for susceptibility so that appropriate antimicrobial therapy for systemic use can be initiated.
Media Articles Related to Neomycin and Polymyxin b Sulfates (Neomycin / Polymyxin b Irrigation)
Infections Nearly Halved After Meningococcal Vaccine Intro in UK
Source: Medscape Allergy & Clinical Immunology Headlines [2016.09.12]
Infant immunization with the Bexsero vaccine led to a 42% decrease in the number of cases of meningococcal B meningitis and septicemia in the first year.
Medscape Medical News
Clinical Trials Related to Neomycin and Polymyxin b Sulfates (Neomycin / Polymyxin b Irrigation)
Effect of Neomycin on the Pharmacokinetics of Regorafenib [Completed]
Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome [Completed]
In this study the investigators aim to compare the efficacy of neomycin to a combination of
rifaximin and neomycin in the treatment of C-IBS subjects with methane on their breath test.
This study will be conducted in collaboration with Dr. John DiBaise at the Mayo Clinic in
Scottsdale, AZ and Dr. Satish Rao in Georgia Regents University in Augusta, GA.
Eradication of Antibiotic-resistant Bacteria Through Antibiotics and Fecal Bacteriotherapy [Not yet recruiting]
This investigator initiated,international, multicenter open-label, randomized controlled
trial aims to assess whether a 5 day course of oral nonabsorbable antibiotics (colistin
sulfate 2 million IU per os 4x/day and neomycin sulfate 500 mg (salt) per os 4x/day )
followed by fecal microbiota transplantation (administered either via nasogastric
administration or via capsules) is effective at eradicating intestinal carriage of
beta-lactamase producing Enterobacteriaceae (ESBL-E) and carbapenemase producing
Enterobacteriaceae (CPE). compared to no intervention (current standard of care) in adult
non-immunosuppressed patients .
Comparison Between Erythromycin and Neomycin Treatment of Hepatic Encephalopathy [Active, not recruiting]
Comparison between the efficacy of two different antibiotics in patients with overt hepatic
encephalopathy. The study is randomized, controlled and double-blinded.
Efficacy of the Combination Bismuth + Neomycin + Procaine in the Treatment of Recurrent Aphthous Ulceration [Completed]
To evaluate the efficacy of the product Bismu-Jet ® (bismuth tartrate and sodium, neomycin
sulfate and procaine hydrochloride) produced by EMS S / A compared to placebo in reducing
the signs and symptoms resulting from UAR in patients of both sexes, with age over 12 years.
Page last updated: 2016-09-12